Arbidol history

Chemical synthesis and screening for
obtaining of ARBIDOL molecule
1965-1970
ARBIDOL preclinical studies
1970-1978
Clinical studies of efficacy and safety in adults
1981-1986
1988
Approved for treatment of A and B influenza in adults
Clinical studies of efficacy and safety in children
1993-1995
1995
Approved for treatment A and B influenza in children
Clinical studies of efficacy and safety in children
2004
2004
Approved for treatment of rotavirus infection in children
Large-scale pharmaco-epidemiological studies
2009-2011
2009
Arbidol can be used from second trimester of pregnancy
Large-scale pharmaco-epidemiological studies "EGIDA"
2009-2015
2009
Reduces the risk of complications: pneumonia, bronchitis, sinusitis, otitis media
Multicentre randomized double blind placebo controlled study "ARBITR"
2011-2017
2014
There are not umifenovir resistant strains
Since 2017, research has been ongoing...

Important Safety Information

Important Safety Information

Active substances. Umifenovirum. АТC Code: J05AX13. INN: Umifenovirum. Pharmacotherapeutic group: antiviral agent. Pharmacodynamics. Arbidol is the antiviral medicinal product. It specifically inhibits in vitro viruses of influenza A and B and other viruses, i.e. agents of Acute Respiratory Virus Infections (ARVI). Based on its antiviral activity mechanism it belongs to the fusion inhibitors (fusions); it interacts with virus hemagglutinin. Contraindications. Hypersensitivity to Umifenovirum or any other component of the medicinal product; Paediatric patients under 2 years old. First trimester of pregnancy. Breast feeding period. Adverse reactions. Rare – allergic reactions.